EA201991283A1 - Фармацевтическая композиция для предотвращения опиоидной зависимости - Google Patents

Фармацевтическая композиция для предотвращения опиоидной зависимости

Info

Publication number
EA201991283A1
EA201991283A1 EA201991283A EA201991283A EA201991283A1 EA 201991283 A1 EA201991283 A1 EA 201991283A1 EA 201991283 A EA201991283 A EA 201991283A EA 201991283 A EA201991283 A EA 201991283A EA 201991283 A1 EA201991283 A1 EA 201991283A1
Authority
EA
Eurasian Patent Office
Prior art keywords
patient
pharmaceutical composition
opioid dependence
composition
preventing opioid
Prior art date
Application number
EA201991283A
Other languages
English (en)
Other versions
EA201991283A9 (ru
Inventor
Кэтрин Стехман-Брин
Джон ДЭВИС
Original Assignee
Ридженерон Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ридженерон Фармасьютикалз, Инк. filed Critical Ридженерон Фармасьютикалз, Инк.
Publication of EA201991283A1 publication Critical patent/EA201991283A1/ru
Publication of EA201991283A9 publication Critical patent/EA201991283A9/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Addiction (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Раскрыта фармацевтическая композиция для предотвращения опиоидной зависимости у пациента. Композиция может быть использована у пациента, страдающего болью в пояснице (LBP) от умеренной до сильной. Композиция полезна для пациента, у которого диагностирована боль в пояснице, и содержит терапевтически эффективное количество антитела, которое специфически связывается с фактором роста нервов (NGF), или его антигенсвязывающего фрагмента; используется в отсутствие опиоида для облегчения боли и предотвращает опиоидную зависимость у пациента.
EA201991283A 2016-11-29 2017-11-28 Фармацевтическая композиция для предотвращения опиоидной зависимости EA201991283A9 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662427365P 2016-11-29 2016-11-29
PCT/US2017/063417 WO2018102294A1 (en) 2016-11-29 2017-11-28 A pharmaceutical composition for averting opioid addiction

Publications (2)

Publication Number Publication Date
EA201991283A1 true EA201991283A1 (ru) 2019-09-30
EA201991283A9 EA201991283A9 (ru) 2019-11-27

Family

ID=60766150

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201991283A EA201991283A9 (ru) 2016-11-29 2017-11-28 Фармацевтическая композиция для предотвращения опиоидной зависимости

Country Status (16)

Country Link
US (2) US10736961B2 (ru)
EP (1) EP3548082B1 (ru)
JP (1) JP7071975B2 (ru)
KR (1) KR20190090820A (ru)
CN (1) CN110072549A (ru)
AU (1) AU2017366870A1 (ru)
BR (1) BR112019010331A2 (ru)
CA (1) CA3045116A1 (ru)
CL (1) CL2019001385A1 (ru)
CO (1) CO2019005247A2 (ru)
EA (1) EA201991283A9 (ru)
IL (1) IL266640B (ru)
MA (2) MA45890B2 (ru)
MX (1) MX2019006013A (ru)
PH (1) PH12019501087A1 (ru)
WO (1) WO2018102294A1 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210043624A (ko) * 2018-08-10 2021-04-21 리제너론 파아마슈티컬스, 인크. 무릎 및/또는 고관절 통증의 안전하고 효과적인 치료를 위한 약제학적 조성물
WO2023092052A1 (en) 2021-11-19 2023-05-25 Regeneron Pharmaceuticals, Inc. Methods and compositions for reducing centralized pain
WO2023212586A1 (en) 2022-04-27 2023-11-02 Regeneron Pharmaceuticals, Inc. Methods for selecting patients for treatment with an ngf antagonist

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
NZ540730A (en) 2002-12-24 2010-09-30 Rinat Neuroscience Corp Anti-NGF antibodies and methods using same
ME00226B (me) 2004-07-15 2011-02-10 Medarex Llc Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade
EP2374818B1 (en) 2006-06-02 2012-12-19 Regeneron Pharmaceuticals, Inc. High affinity antibodies to human IL-6 receptor
MY153781A (en) 2007-08-10 2015-03-13 Regeneron Pharma High affinity human antibodies to human nerve growth factor
SG189220A1 (en) 2010-10-06 2013-05-31 Regeneron Pharma Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies

Also Published As

Publication number Publication date
PH12019501087A1 (en) 2019-08-19
WO2018102294A1 (en) 2018-06-07
MA45890B2 (fr) 2022-10-31
AU2017366870A1 (en) 2019-06-06
MX2019006013A (es) 2019-10-14
MA46951A (fr) 2019-10-09
EP3548082A1 (en) 2019-10-09
KR20190090820A (ko) 2019-08-02
US10736961B2 (en) 2020-08-11
US20210060159A1 (en) 2021-03-04
IL266640A (en) 2019-07-31
BR112019010331A2 (pt) 2019-10-22
IL266640B (en) 2022-09-01
US20180147280A1 (en) 2018-05-31
EP3548082B1 (en) 2024-05-15
CL2019001385A1 (es) 2019-07-26
CA3045116A1 (en) 2018-06-07
CN110072549A (zh) 2019-07-30
EA201991283A9 (ru) 2019-11-27
US11491222B2 (en) 2022-11-08
MA45890A1 (fr) 2020-02-28
CO2019005247A2 (es) 2019-05-31
JP2019535716A (ja) 2019-12-12
JP7071975B2 (ja) 2022-05-19

Similar Documents

Publication Publication Date Title
UA118453C2 (uk) Спосіб лікування пухлин у пацієнта
PH12018500174A1 (en) Combined use of anti pd-1 and anti m-csf antibodies in the treatment of cancer
MA47313B1 (fr) Formulations sous-cutanées d'anticorps her2
EA201890145A1 (ru) Антитела к фактору xi и способы их применения
EA201891495A1 (ru) Биспецифические анти-cd20/анти-cd3 антитела для лечения острого лимфобластного лейкоза
EA201691225A1 (ru) Антитело к pd-1, его антигенсвязывающий фрагмент и их медицинское применение
EA201691438A1 (ru) Антитело, которое связывается с erbb-2 и erbb-3
EA201600190A1 (ru) Анти-prlr антитела и их применение
MX2015010749A (es) Anticuerpos humanos para nav1.7.
EA201591019A1 (ru) СПОСОБ СНИЖЕНИЯ КОЛИЧЕСТВА АМИЛОИДНЫХ БЛЯШЕК В ГОЛОВНОМ МОЗГЕ ПРИ ПОМОЩИ АНТИ-Aβ АНТИТЕЛ
EA201892541A1 (ru) Гуманизированные анти-il-1r3 антитела
EA201592203A1 (ru) Способы лечения таупатии
EA201991511A1 (ru) Кристаллическая структура гремлин-1 и ингибирующее антитело
EA202092420A1 (ru) Антитело против pd-l1 и его применение
EA201991283A1 (ru) Фармацевтическая композиция для предотвращения опиоидной зависимости
MX2022001796A (es) Metodos y composiciones para inhibir los sintomas asociados con la veisalgia.
EA202191666A1 (ru) Антитела к il-27 и их применение
EP3991749A3 (en) A therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody
EA202092225A1 (ru) Соединения и их применение
MX2021011995A (es) Composicion farmaceutica acuosa de anticuerpo anti-il17a y su uso.
EA201990559A1 (ru) Комбинированная терапия
EA202190504A1 (ru) Способы лечения псориаза
BR112018006900A2 (pt) anticorpo ou um seu fragmento antígeno-ligante que especificamente se liga a erbb3, composição farmacêutica, e método para a prevenção ou tratamento de uma doença relacionada com a ativação ou a superexpressão da proteína erbb3 em um indivíduo
EA201990041A1 (ru) Композиции, содержащие тимолол, и их применение при лечении розацеа при местном применении
EA202092481A1 (ru) Комбинированный способ лечения антагонистом cd73 и антагонистом оси pd-1/pd-l1